Driver mutations such as DNMT3A, TET2, IDH2, TP53, RUNX1, NPM1, NRAS, FLT3-ITD, FLT3-TKD, ASXL1 and STAG2 are often enriched in elderly AML patients (>65–70 years old), thereby differing in type and prevalence from those encountered in younger patients, who exhibit a comparatively different mutational landscape [19,26,40]. Here, ASXL1 is linked to acute myeloid leukemia.